

NOVO-NORDISK AS B

ISIN: DK0062498333 WKN: -

Overview

2024/07/17 15:34:34

Price
124.12 EURDifference  -4.57% (-5.94)

General attributes

| | |
|----------------|------------------------------------|
| ISIN | DK0062498333 |
| Symbol | NOVO B |
| Exchange | Hanover |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 410,869 EUR |
| Benchmark | OMX COPENHAGEN 20 |

Market data

| | |
|-------------------|------------|
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 128.84 EUR |
| High | 128.84 EUR |
| Low | 124.12 EUR |
| Close (prev. day) | 130.06 EUR |
| VWAP | - |
| Volume (pcs) | 75 |
| Trading volume | 9,309.00 |
| Number of trades | 2 |
| Last size | 75 |

Futures and Options

| | |
|-----------------|----|
| Related Futures | 30 |
| Related Options | - |

PDF Downloads

Company report: NOVO-NORDISK AS B 

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

| on sector | | | |
|------------|---|-----------------------|---|
| Date | | Headline | Download |
| 2024/07/12 |  | Global Equity Ratings |  |
| 2024/06/21 |  | Global Equity Ratings |  |
| 2024/06/14 |  | Global Equity Ratings |  |
| 2024/05/29 |  | Global Equity Ratings |  |
| 2024/04/26 |  | Global Equity Ratings |  |

Details

2024/07/17 15:34:34

Price

124.12 EUR

Difference ▼ -4.57% (-5.94)

General attributes

ISIN DK0062498333

Symbol NOVO B

Exchange Hanover

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 410,869 EUR

Benchmark OMX COPENHAGEN 20

Market data

Bid (Bid size) -

Ask (Ask size) -

Open 128.84 EUR

High 128.84 EUR

Low 124.12 EUR

Close (prev. day) 130.06 EUR

VWAP -

Volume (pcs) 75

Trading volume 9,309.00

Number of trades 2

Last size 75

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|---------|---------|----------|
| Perf (%) | +26.85% | +72.63% | +235.78% |
| Perf (abs.) | +26.27 | +52.22 | +87.16 |
| Beta | 1.36 | 1.43 | 1.27 |
| Volatility | 30.27 | 33.38 | 32.15 |



Information about previous performance does not guarantee future performance.

Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.) 128.88 EUR (82)

Ø price 30 days | Ø volume 30 days (pcs.) 131.90 EUR (46)

Ø price 100 days | Ø volume 100 days (pcs.) 123.03 EUR (54)

Ø price 250 days | Ø volume 250 days (pcs.) 104.86 EUR (64)

YTD High | date 138.82 EUR (2024/06/26)

YTD Low | date 93.00 EUR (2024/01/03)

52 Weeks High | date 138.82 EUR (2024/06/26)

52 Weeks Low | date 71.20 EUR (2023/07/18)

All listings for NOVO-NORDISK AS B

| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
|-----------------------|------------|-------|------------|-----------------------|------------------|
| Xetra | 2024/07/17 | 17:35 | 123.82 EUR | 13.76 | 2,317 |
| Vienna Stock Exchange | 2024/07/17 | 17:32 | 123.58 EUR | 0.07 | 23 |
| Tradegate | 2024/07/17 | 22:26 | 123.86 EUR | 16.04 | 1,329 |
| Stuttgart | 2024/07/17 | 21:48 | 123.32 EUR | 0.54 | 51 |
| Nasdaq Copenhagen | 2024/ | 17:20 | 919.00 DKK | 3,279.57 | 48,199 |

| | | | | | | |
|---|----------------|-------|------------|-------|--|-----|
| | 07/17 | | | | | |
| Munich | 2024/ 07/17 | 17:36 | 123.86 EUR | 0.02 | | 4 |
| London Stock Exchange European Trade Reporting | 2024/ 07/17 | 16:55 | 934.15 DKK | 24.92 | | 142 |
| Hanover | 2024/ 07/17 | 15:34 | 124.12 EUR | 0.01 | | 2 |
| Hamburg | 2024/ 07/17 | 18:41 | 123.46 EUR | 0.01 | | 4 |
| Frankfurt | 2024/ 07/17 | 21:36 | 124.12 EUR | 1.48 | | 144 |
| FINRA other OTC Issues | 2024/ 07/17 | 21:59 | 134.25 USD | 0.26 | | 44 |
| Duesseldorf | 2024/ 07/17 | 20:25 | 124.70 EUR | 0.03 | | 13 |
| Berlin | 2024/ 07/17 | 09:56 | 126.74 EUR | 0.01 | | 3 |

Company profile

Company Logo



Contact Details

NOVO NORDISK A/S

--

Novo Allé 1 - 2880 Bagsværd

Telefon: +45-44-44-88-88

Fax: +

E-mail: -

PDF Downloads

Company report: NOVO-NORDISK AS B 

Company Profile

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 and is headquartered in Bagsværd, Denmark.

Members of Management Board

| | |
|---------------------------|-------------------------------|
| Lars Fruergaard Jørgensen | Chairman of Managing Board |
| Camilla Sylvest | Member of Executive Committee |
| David Moore | Member of Executive Committee |
| Doug Langa | Member of Executive Committee |
| Henrik Wulff | Member of Executive Committee |
| Karsten Munk Knudsen | Member of Executive Committee |
| Ludovic Helfgott | Member of Executive Committee |
| Marcus Schindler | Member of Executive Committee |
| Martin Holst Lange | Member of Executive Committee |
| Maziar Mike Doustdar | Member of Executive Committee |
| Tania Sabroe | Member of Executive Committee |

Board of directors

| | |
|-----------------------|-------------------------------|
| Helge Lund | Chairman of Supervisory Board |
| Martin MacKay | Member of Supervisory Board |
| Sylvie Grégoire | Member of Supervisory Board |
| Andreas Fibig | Member of Supervisory Board |
| Christina Law | Member of Supervisory Board |
| Elisabeth Christensen | Member of Supervisory Board |
| Henrik Poulsen | Member of Supervisory Board |
| Kasim Kutay | Member of Supervisory Board |
| Laurence Debroux | Member of Supervisory Board |
| Liselotte Hyvedel | Member of Supervisory Board |
| Mette Bøjer Jensen | Member of Supervisory Board |
| Thomas Rantzau | Member of Supervisory Board |